Can Agenus turn botensilimab and balstilimab into a serious post-ICI liver cancer contender?
Post-ICI liver cancer has few strong options. Agenus’ BOT plus BAL data raise the next question: can durability survive larger trials?
Pharma & Biotech
Pharma & Biotech
Drug Farm’s DF-003 shows early signal in ROSAH syndrome, but can ALPK1 inhibition hold up in pivotal testing?
Drug Farm’s DF-003 showed early Phase 1b benefit in ROSAH syndrome. Read what the ALPK1 data could change next.